[PDF] Top 20 ORAL HYPOGLYCEMIC AGENT OVERVIEW

... Sulfonylureas, derived from sulfonic acid and urea, were initially developed in the 1950's and have remained a cornerstone of therapy for type 2 diabetes. The combination of their proven efficacy in most patients, low ... See full document

... the oral route scores over the others for the ease and comfort with which the therapeutic agent can be administered to the ...make oral insulin delivery a ...achieve hypoglycemic effect in ... See full document

... and oral medications. Oral hypoglycemic agents are also useful in the treatment of type 2 ...DM. Oral hypoglycemic agents include sulphonylureas, biguanides, meglitinide, DPP-IV ... See full document

... Metformin (N,N-dimethyl biguanide) is an oral anti-diabetic drug regularly used for the treatment of Type 2 diabetes mellitus, mainly in obese patients. They reduce hepatic glucose output and increase uptake of ... See full document

... an oral hypoglycemic agent, which is a most commonly used drug for the treatment of type II diabetes ...The oral absorption of Glipizide is uniform, rapid and complete with a bioavailability ... See full document

... Diabetes mellitus is one of the most common endocrine metabolic disorders, which has caused significant morbidity and mortality due to various microvascular and macrovascular complications Diabetes has become the third ... See full document

... Diabetes mellitus (DM) is a worldwide rising concern that leads to an increased rate of morbidity, mortality, and health-care costs. DM is a chronic, endocrine disorder associated with hyperglycemia. The current ... See full document

... Cheng’s, et al. study [12] further exposed the limita- tions of the administrative database. The authors con- ducted a retrospective cohort study of women diagnosed with GDM who required pharmaceutical therapy. They were ... See full document

... Methods: Maternal details were obtained and physical examination was performed on the neonates. Babies were given hourly feeds soon after birth and blood glucoses checked at 1, 3, 5, 9 and 12 hours of life; Hematocrit ... See full document

... more hypoglycemic activity. The hypoglycemic effect of glimepiride as well as metal complex were investigated on the blood sugar levels of male wistar rats by alloxan induced antidiabetic test (Seshadri ... See full document

... The CONSORT flow diagram for this trial has been published elsewhere (Bogner et al., 2012). In brief, of 715 patients with type 2 DM were identified by electronic medical records. In all, 265 were eligible based on ... See full document

... several oral hypoglycemic agents present in the market, each agent with its particular mechanism and site of action; hence the glucose lowering effects and costs of medication among patients is ... See full document

... Several clinical practice guidelines recommend a step- wise treatment pathway for diabetes. Diet control and lifestyle intervention are considered the cornerstones for treatment of DM according to these guidelines. How- ... See full document

... the oral cavity to provide rapid local or systemic drug ...first oral thin film product to incorporate a drug and were introduced in the United States in September, 2003 by Prestige Brands international for ... See full document

... Several oral therapies are approved for use in combination with metformin; however, they are not always effective and are associated with side effects ...an agent that could improve β-cell function, improve ... See full document

... tiple oral hypoglycemic agent use, presence of hypertension or chronic kidney disease, longer duration of diabetes, low or high glucose level, and high Charlson Comorbidity Index score were found to ... See full document

... The slow absorption rate of drug usually originates from either poor dissolution of drug from the formulation or poor permeability of drug across gastrointestinal membrane. For poorly water soluble and highly permeable ... See full document

... The term controlled release implies a system that provides continuous delivery of the drug for a predetermined period with predictable and reproducible kinetics and a known mechanism of release. Also included in this ... See full document

... The aim of this study was to evaluate safety and efficacy of oral hypoglycemic agents in obese Type-2 diabetic patients. The objectives are to compare fasting and postprandial blood sugar (PPBS) levels, to ... See full document

... conventional oral hypoglycemic agent, which would result in more side effects, a combination of the low dose oral hypoglycemic agent with low dose or even higher dose of MI ... See full document